Comparative Pharmacology
Head-to-head clinical analysis: ETHACRYNIC ACID versus FUROSEMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETHACRYNIC ACID versus FUROSEMIDE.
ETHACRYNIC ACID vs FUROSEMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits sodium-potassium-chloride cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, leading to increased excretion of sodium, chloride, potassium, and water. Also inhibits prostaglandin degradation.
Furosemide is a loop diuretic that inhibits the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium ions, leading to increased urine output.
50 to 100 mg orally once daily; may increase by 25 to 50 mg increments at intervals of 2 to 3 days up to 400 mg/day. IV: 0.5 to 1 mg/kg slowly (over several minutes); usual initial dose 50 mg.
Adults: 20-80 mg orally once or twice daily; IV/IM: 20-40 mg once or twice daily, may increase by 20-40 mg every 6-8 hours. Max dose: 600 mg/day.
None Documented
None Documented
Clinical Note
moderateFurosemide + Digoxin
"The risk or severity of adverse effects can be increased when Furosemide is combined with Digoxin."
Clinical Note
moderateFurosemide + Digitoxin
"The risk or severity of adverse effects can be increased when Furosemide is combined with Digitoxin."
Clinical Note
moderateFurosemide + Deslanoside
"The risk or severity of adverse effects can be increased when Furosemide is combined with Deslanoside."
Clinical Note
moderateFurosemide + Acetyldigitoxin
Terminal elimination half-life is approximately 2-4 hours in patients with normal renal function; may be prolonged in renal impairment.
0.5-2 hours (terminal); prolonged in renal impairment (up to 9-24 hours) and hepatic cirrhosis (up to 2-4 hours).
Primarily renal (approximately 60-70% as unchanged drug and metabolites) with some biliary/fecal excretion (approximately 30-40%).
Renal (50-80% unchanged; remainder as glucuronide metabolite); fecal (<2%).
Category C
Category A/B
Loop Diuretic
Loop Diuretic
"The risk or severity of adverse effects can be increased when Furosemide is combined with Acetyldigitoxin."